ARS Pharmaceuticals (SPRY) Current Assets (2020 - 2026)

ARS Pharmaceuticals has disclosed Current Assets across 7 years of filings, most recently posting $245.2 million for Q1 2026.

• Current Assets for Q1 2026 came in at $245.2 million, down 19.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $245.2 million (down 19.29% YoY), and the FY2025 annual result was $284.9 million, down 14.78% from the prior year.
• Current Assets came in at $245.2 million for Q1 2026 at ARS Pharmaceuticals, down from $284.9 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $338.9 million in Q3 2025 to a low of $208.8 million in Q3 2024.
• The 5-year median for Current Assets is $263.1 million (2022), against an average of $265.6 million.
• Peak annual rise in Current Assets reached 357.27% in 2022, while the deepest fall reached 30.93% in 2022.
• ARS Pharmaceuticals' Current Assets stood at $277.7 million in 2022, then slipped by 16.56% to $231.7 million in 2023, then surged by 44.26% to $334.3 million in 2024, then fell by 14.78% to $284.9 million in 2025, then slipped by 13.92% to $245.2 million in 2026.
• The last three Current Assets figures came in at $245.2 million (Q1 2026), $284.9 million (Q4 2025), and $338.9 million (Q3 2025), per Business Quant data.